Head-to-head · WeighScore
No BS RX vs SkinnyRx
By GLP-1 ScorecardUpdated
Score comparison
No BS RX has the higher recorded score — 82.8/100 to 60.5/100.
No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Twenty-four prices on one public page, four dispensing pharmacies named with street addresses, and a no-intro-rate promise the arithmetic actually supports.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | No BS RX | SkinnyRx |
|---|---|---|
| WeighScore | 82.8/100 | 60.5/100 |
| Grade | B− | C |
| Site position | #24 | #284 |
| Semaglutide | $179/mo month-to-month (a separate low-dose program is $140) | Injection advertised $99 first month; compounded tablets $149 first month. Confirm the recurring price, selected term and usable prescription supply. |
| Tirzepatide | $249/mo month-to-month (a separate low-dose program is $140) | Injection advertised $99 first month; compounded dissolving tablets $199 first month. Confirm the recurring price, selected term and usable prescription supply. |
| Coverage | Not publicly listed | Current terms exclude certain compounded offerings in Alabama, Louisiana and Mississippi; confirm eligibility for the exact route and pharmacy. |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Yes | Yes |
Site position #24 · B−
Strengths
- Names four dispensing pharmacies with street addresses and telephone numbers — Red Rock Compounding Pharmacy, Health Warehouse, Precision Medicine and Triad Rx
- "No Fake Intro Rate — the price on the page is the ongoing program price" is a named commitment, and the $140 in its hero really is a month-to-month rate on a real product
- Every program row prints "503A pharmacy fulfillment" and "No dose-based price changes" on the table itself
- Six programs across four terms are published with no intake and no account
- A sleep program is priced on the same page, including a diagnostic ring study at $33/mo
What to consider
- The same $409 twelve-week block appears under three different monthly rates — an $11 saving against one and a $128 saving against another, styled identically
- The low-dose programs stop at twelve weeks; only the standard programs carry 24- and 52-week rungs
- The Terms name four pharmacies and no operating company
- State availability is not published, and there is no FDA-approved brand lane
Site position #284 · C
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Strengths
- Advertises separate first-month prices for both compounded molecules and both injection and tablet routes
- Current terms describe the ninety-day commercial guarantee’s dose logging, claim-window, promotional eligibility and coverage requirements
- Names a medical director/advisor in public information; this does not identify the assigned treating professional
- Publishes compounded-treatment state exclusions and cancellation channels rather than leaving every operational detail unspecified
What to consider
- First-month prices do not establish the recurring amount, selected full prepayment or usable medication quantity
- Cancellation requires five days’ notice before renewal processing, which can itself precede the next subscription period
- The guarantee’s bundled-refund language needs clarification alongside general third-party-fee deductions, medication-return requirements and product FAQ restrictions
- Microdose badges and daily tablet descriptions do not establish a separate price, complete prescription or equivalent branded-treatment results
- The actual prescribing practice, assigned clinician, dispensing pharmacy, physical compounder and patient-lab costs remain unconfirmed
- The named advisor’s Florida record flags discipline and a public complaint, while Oregon lists a surrendered license; neither record determines every clinician’s authority or the patient assignment
- FDA issued Lean Rx Inc. dba SkinnyRx a warning letter on February 20, 2026; website testing claims do not establish independent pharmacy verification.
Featured provider
SkinnyRx
SkinnyRx scores 60.5/100 (C). Publishes four introductory compounded-treatment offers, but continuing costs, usable supply and the interaction between cancellation and refund rules need confirmation.
Commercial relationships affect this placement. The score comparison above is separate.
FDAWarning letter issued to Lean Rx, Inc. dba SkinnyRx in February 2026. See the FDA warning-letter database.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.